Mandate

Vinge advises Intera Partners in connection with the investment in Yellow Elk

January 15, 2025

Vinge has advised the Nordic private equity firm Intera Partners in connection with its investment in the AI and data analytics firm Yellow Elk.

Yellow Elk offers high-level expertise within data analytics and AI, spanning from data engineering to machine learning, presentation, analysis and broader advisory, including enterprise and data architecture as well as data-driven change. Founded in 2018, Yellow Elk has a turnover of SEK 150 million and employs around 90 professionals in data and analytics in Sweden. Yellow Elk has been recognized by Dagens Industri as a fast-growing “Gasell” company for the past three years.

The transaction is subject to regulatory approvals.

Vinge’s team consisted of Jonas Johansson, Egil Svensson and Helena Liljenberg (M&A), Helena Göransson and Karl-Gustaw Tobola (Banking and Finance), Mario Saad and Jacob Eberil (Commercial Agreements), Simon Söderholm and Agnes Pigg (Employment), Johan Gavelin (IP), Katja Häglund (IT and GDPR), Madelene Andersson and Sara Franson (Real Estate), Daniel Wendelsson, Martin Hammarskiöld and Lovisa Arpi (Regulatory).

Read the client’s press release.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025